Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2022-04-06
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is being done to collect samples of tumor tissues, matched normal tissue when possible, and approximately 50 mL of blood.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
NCT05600933
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples
NCT02239575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The collected tissue specimens will be used to develop preclinical models; i.e., cell lines, patient derived micro-cancer models as well as patient-derived xenograft models. In this study we may profile tumors using genomic and/or proteomic approaches to identify targetable alterations in tumor tissue from patients. To assure that the derived cell lines and micro-cancer models have not been cross contaminated during development with other models in development, DNA sequencing may be used. Using these preclinical models, we will test new therapies in vitro, or in vivo in mice in order to identify novel therapeutics as well as interrogate genes for their role in tumor biology. Guidance for molecular targeted therapy will involve gene analysis of oncogenes and tumor suppressor genes. Results from these studies may provide the rationale for the design of future novel clinical trials. The evaluation of these preclinical models may lead to predictive value related to patient response to therapy as well as clinical trials. With consent, these models may be shared with other investigators internal or external to Mayo Clinic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tissue Collection
Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
Tissue Collection
Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
Blood Collection
Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional testing
Blood Collection
Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional
Buccal Swab
Buccal swab may be requested, if necessary, to generate germline data.
Buccal Swab
Buccal swab may be requested, if necessary, to generate germline data.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tissue Collection
Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
Blood Collection
Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional
Buccal Swab
Buccal swab may be requested, if necessary, to generate germline data.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is a good medical candidate for a standard of care or research biopsy or surgical procedure to obtain tissue
Exclusion Criteria
* Institutionalized or incarcerated patients
* Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use
* Biopsy must not be considered more than minimal risk to the patient.
* Have a contraindication to percutaneous biopsy including:
1. Significant coagulopathy that cannot be adequately corrected.
2. Severely compromised cardiopulmonary function or hemodynamic instability.
3. Lack of a safe pathway to the lesion per the interventional radiologist.
4. Inability of the patient to cooperate with, or to be positioned for, the procedure.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aaron S. Mansfield, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-008831
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.